STING Pathway:

Using a Tumor’s Composition to Activate an Immune Response

Learn More

APRIL Pathway:

Modulating Cancer Immunity 

Learn More

Immunotherapy

Learn how immunotherapies harness a person’s immune system to fight cancer

Learn More

Clinical Trials

Learn more about Aduro’s clinical programs

Learn More

Investors

Download the 2017 Annual Report

Download PDF

Recent News

February 11, 2019 Aduro Announces First Patient Dosed in Phase 1 Study of ADU-S100 (MIW815) in Combination with YERVOY (ipilimumab) for the Treatment of Relapsed and Refractory Melanoma

January 30, 2019 Aduro Biotech Announces Strategic Reset

January 03, 2019 Aduro Biotech to Present at the 37th Annual J.P. Morgan Healthcare Conference

Read More

Careers

Are you interested in working for a company where interactions are authentic, commitment is high and people excel together?

Learn More